Main Conference Day 2Wednesday, 11 June 2025 - BST (British Summer Time, GMT+1)

Alchemab’s approach to developing therapeutic antibodies is based on the concept that the immune system is able to generate protective autoantibodies which drive unusual disease resilience. By deep sequencing the B Cell Receptor repertoires of groups of resilient individuals and looking for convergence antibody sequences shared in these individuals, we can identify those rare protective antibodies, identify the targets they bind and harness and develop them into novel therapies. This approach has been successfully applied in neurodegenerative conditions and examples will be presented.

The Dropzylla® Technology is a high-throughput microfluidic platform designed for the cloning of antibody repertoires. These recombinant repertoires are used to identify best-in-class antibodies targeting cancer and viral infections. MTx’ lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat BK virus infections in kidney transplant recipients. The oncology program aims to discover novel antibody-target pairs directly from tumor B cells.

We present a novel discovery platform that seamlessly combines in vivo immunisation with in vitro antibody discovery by leveraging a novel microfluidics-based semi-permeable capsule technology for recovery of natively-paired VH:VL (scFv) repertoires from millions of B cells derived from immunised animals and integrating it with our cutting-edge mammalian IgG display platform. This innovative capability enables iterative screening of original immune repertoires in final IgG format and early selection of highly developable, target-specific antibodies, thereby improving therapeutic discovery workflows.

Deep Screening is a novel high throughput method for the rapid and massive parallel screening of biologics. It enables the experimental collection of up to 10^9 scFv sequences paired with binding affinities in a 3 day experiment, identifying hits where traditional methods fail. Here we will present recent work conducted at Sortera.

PolyMap is a high-throughput method for mapping thousands of protein-protein interactions in a single tube. Here we probe antibody libraries isolated from human donors against a set of SARS-CoV-2 spike variants to demonstrate how PolyMap can be used to profile immune responses, map epitopes of hundreds of antibodies, and select functionally distinct clones for therapeutics.